HARVARD BIOSCIENCE INC (HBIO) Fundamental Analysis & Valuation

NASDAQ:HBIO • US4169061052

Current stock price

5.2 USD
+0.11 (+2.16%)
Last:

This HBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. HBIO Profitability Analysis

1.1 Basic Checks

  • In the past year HBIO has reported negative net income.
  • HBIO had a positive operating cash flow in the past year.
  • HBIO had negative earnings in each of the past 5 years.
  • Each year in the past 5 years HBIO had a positive operating cash flow.
HBIO Yearly Net Income VS EBIT VS OCF VS FCFHBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M

1.2 Ratios

  • The Return On Assets of HBIO (-70.81%) is worse than 91.07% of its industry peers.
  • HBIO has a worse Return On Equity (-412.84%) than 89.29% of its industry peers.
Industry RankSector Rank
ROA -70.81%
ROE -412.84%
ROIC N/A
ROA(3y)-27.7%
ROA(5y)-17.96%
ROE(3y)-145.7%
ROE(5y)-90.12%
ROIC(3y)N/A
ROIC(5y)N/A
HBIO Yearly ROA, ROE, ROICHBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • The Gross Margin of HBIO (57.67%) is better than 71.43% of its industry peers.
  • HBIO's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for HBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.6%
GM growth 5Y0.3%
HBIO Yearly Profit, Operating, Gross MarginsHBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. HBIO Health Analysis

2.1 Basic Checks

  • HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, HBIO has more shares outstanding
  • The number of shares outstanding for HBIO has been increased compared to 5 years ago.
  • HBIO has a worse debt/assets ratio than last year.
HBIO Yearly Shares OutstandingHBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
HBIO Yearly Total Debt VS Total AssetsHBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -0.20, we must say that HBIO is in the distress zone and has some risk of bankruptcy.
  • HBIO has a Altman-Z score of -0.20. This is in the lower half of the industry: HBIO underperforms 69.64% of its industry peers.
  • HBIO has a debt to FCF ratio of 7.37. This is a slightly negative value and a sign of low solvency as HBIO would need 7.37 years to pay back of all of its debts.
  • The Debt to FCF ratio of HBIO (7.37) is better than 64.29% of its industry peers.
  • HBIO has a Debt/Equity ratio of 2.61. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 2.61, HBIO is doing worse than 87.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF 7.37
Altman-Z -0.2
ROIC/WACCN/A
WACC11.25%
HBIO Yearly LT Debt VS Equity VS FCFHBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M

2.3 Liquidity

  • HBIO has a Current Ratio of 2.20. This indicates that HBIO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.20, HBIO is in line with its industry, outperforming 46.43% of the companies in the same industry.
  • A Quick Ratio of 1.25 indicates that HBIO should not have too much problems paying its short term obligations.
  • HBIO's Quick ratio of 1.25 is on the low side compared to the rest of the industry. HBIO is outperformed by 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 1.25
HBIO Yearly Current Assets VS Current LiabilitesHBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. HBIO Growth Analysis

3.1 Past

  • HBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -133.33%.
  • The Revenue has decreased by -8.06% in the past year.
  • The Revenue has been decreasing by -3.25% on average over the past years.
EPS 1Y (TTM)-133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-8.06%
Revenue growth 3Y-8.59%
Revenue growth 5Y-3.25%
Sales Q2Q%-3.34%

3.2 Future

  • HBIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 249.28% yearly.
  • The Revenue is expected to grow by 5.99% on average over the next years.
EPS Next Y584.5%
EPS Next 2Y249.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.49%
Revenue Next 2Y5.99%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HBIO Yearly Revenue VS EstimatesHBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
HBIO Yearly EPS VS EstimatesHBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 2

More info and screens

Find the best growth stocksShow best growing peers

6

4. HBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • HBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • HBIO is valuated cheaply with a Price/Forward Earnings ratio of 5.37.
  • HBIO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HBIO is cheaper than 100.00% of the companies in the same industry.
  • HBIO is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 5.37
HBIO Price Earnings VS Forward Price EarningsHBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HBIO is on the same level as its industry peers.
  • Based on the Price/Free Cash Flow ratio, HBIO is valued a bit cheaper than the industry average as 60.71% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 47.79
EV/EBITDA 47.36
HBIO Per share dataHBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • HBIO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • HBIO's earnings are expected to grow with 249.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y249.28%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HBIO Dividend Analysis

5.1 Amount

  • HBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HBIO Fundamentals: All Metrics, Ratios and Statistics

HARVARD BIOSCIENCE INC

NASDAQ:HBIO (4/2/2026, 8:00:01 PM)

5.2

+0.11 (+2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners51.1%
Inst Owner Change28.36%
Ins Owners3.73%
Ins Owner Change1.48%
Market Cap232.54M
Revenue(TTM)86.55M
Net Income(TTM)-56.70M
Analysts80
Price Target6.12 (17.69%)
Short Float %N/A
Short Ratio1.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-100%
Min EPS beat(2)-100%
Max EPS beat(2)-100%
EPS beat(4)2
Avg EPS beat(4)-30.64%
Min EPS beat(4)-100%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-49.3%
EPS beat(12)4
Avg EPS beat(12)-42.66%
EPS beat(16)5
Avg EPS beat(16)-40.85%
Revenue beat(2)2
Avg Revenue beat(2)0.84%
Min Revenue beat(2)0.73%
Max Revenue beat(2)0.94%
Revenue beat(4)3
Avg Revenue beat(4)2.78%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)11.18%
Revenue beat(8)3
Avg Revenue beat(8)-3.14%
Revenue beat(12)4
Avg Revenue beat(12)-3.71%
Revenue beat(16)4
Avg Revenue beat(16)-4.33%
PT rev (1m)200%
PT rev (3m)200%
EPS NQ rev (1m)-12000%
EPS NQ rev (3m)-12000%
EPS NY rev (1m)900%
EPS NY rev (3m)900%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)-4%
Revenue NY rev (3m)-3.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.37
P/S 2.69
P/FCF 47.79
P/OCF 34.56
P/B 16.93
P/tB N/A
EV/EBITDA 47.36
EPS(TTM)-0.2
EYN/A
EPS(NY)0.97
Fwd EY18.63%
FCF(TTM)0.11
FCFY2.09%
OCF(TTM)0.15
OCFY2.89%
SpS1.94
BVpS0.31
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.81%
ROE -412.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.67%
FCFM 5.62%
ROA(3y)-27.7%
ROA(5y)-17.96%
ROE(3y)-145.7%
ROE(5y)-90.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.6%
GM growth 5Y0.3%
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF 7.37
Debt/EBITDA 6.54
Cap/Depr 31.34%
Cap/Sales 2.15%
Interest Coverage N/A
Cash Conversion 122.66%
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 1.25
Altman-Z -0.2
F-Score4
WACC11.25%
ROIC/WACCN/A
Cap/Depr(3y)36.65%
Cap/Depr(5y)29.73%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y584.5%
EPS Next 2Y249.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.06%
Revenue growth 3Y-8.59%
Revenue growth 5Y-3.25%
Sales Q2Q%-3.34%
Revenue Next Year3.49%
Revenue Next 2Y5.99%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y91.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year125.1%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y366.92%
FCF growth 3YN/A
FCF growth 5Y-9.87%
OCF growth 1Y367.29%
OCF growth 3Y80.2%
OCF growth 5Y-6.33%

HARVARD BIOSCIENCE INC / HBIO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of HARVARD BIOSCIENCE INC (HBIO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to HBIO.


Can you provide the valuation status for HARVARD BIOSCIENCE INC?

ChartMill assigns a valuation rating of 6 / 10 to HARVARD BIOSCIENCE INC (HBIO). This can be considered as Fairly Valued.


What is the profitability of HBIO stock?

HARVARD BIOSCIENCE INC (HBIO) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for HBIO stock?

The Earnings per Share (EPS) of HARVARD BIOSCIENCE INC (HBIO) is expected to grow by 584.5% in the next year.